StackwiseStackwise
medication

Rivaroxaban

Also known as: Xarelto

Chemical structure of Rivaroxaban (PubChem CID 9875401)
Structure via PubChem
Half-life
8 h
Typical timing
with_meal
Food rule
with food
Default unit
mg

Overview

Rivaroxaban, commonly known by its brand name Xarelto, is an anticoagulant medication belonging to a class of drugs called direct oral anticoagulants (DOACs). Its primary function is to reduce the risk of blood clot formation. It is approved for various conditions where preventing clot formation is critical, such as in individuals with non-valvular atrial fibrillation to prevent stroke and systemic embolism, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and for the reduction in risk of recurrent DVT and PE. It is also used to prevent DVT and PE in patients undergoing hip or knee replacement surgery. In some cases, it may be used in combination with aspirin to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) (FDA label, EMA SmPC). Unlike older anticoagulants like warfarin, rivaroxaban does not require routine blood monitoring to adjust the dose, although monitoring may be performed in specific clinical situations. It is administered orally and works by directly inhibiting a specific clotting factor in the blood (PubChem, DrugBank).

Deep dive

Tap a section to expand.

Known interactions

  • Category rule: supplement × medication
    Note

    Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).

    Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.

  • Category rule: vitamin × medication
    Note

    Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).

    Specific pairs are checked against a licensed source; confirm with your provider.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Additive antiplatelet/antithrombotic effect increases bleeding risk.

    Discuss with prescribing clinician; monitor for bruising, prolonged bleeding, and dose adjustments.

  • Compound-pair rule
    Caution

    Vitamin K reverses vitamin K antagonist activity and shifts INR.

    Keep vitamin K intake consistent; do not start or stop supplementation without INR monitoring.

  • Compound-pair rule
    Caution

    Vitamin K2 can shift INR on warfarin.

    Discuss with prescribing clinician before adding K2.

Frequently asked

Sources referenced

* Cochrane Library * DrugBank * Examine.com * European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) * U.S. Food and Drug Administration (FDA) label * Mayo Clinic * MedlinePlus * National Institutes of Health (NIH) Office of Dietary Supplements (ODS) * PubChem

Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.

Related compounds

Others in the medication category or studied for the same goals.

Track Rivaroxaban in Stackwise

Add it to your stack. We'll schedule doses, check interactions against everything else you take, and remind you at the right time.

Sign up free →